A Phase I Study of DE-766 with Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Cancer

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221282

Enrollment

Registered

2010-10-25

Start date

2010-10-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

investigational material(s) Generic name etc : DE-766 INN of investigational material : nimotuzumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stage II, III (non-T4), or IV (non-T4 and M1 lymph nodes) esophageal cancer, who considered suitable to undergo definitive radiotherapy Patients without a history of esophageal cancer treatment and without a history of previous treatment of other malignant tumors

Exclusion criteria

Exclusion criteria: Patients with another active malignancy Patients with severe esophageal stenosis or esophago-mediastinal fistula Patients with any of the severe or uncontrolled complications

Design outcomes

Primary

Measure	Time frame
Dose limiting toxicity and maximum tolerated dose CTCAE(Ver.4.0)	—

Secondary

Measure	Time frame
Adverse events, pharmacokinetic, anti-tumor effects, complete response rate, progression-free survival, overall survival rate CTCAE(Ver.4.0), RECIST(Ver.1.1)	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026